| Stage | CRUS | % of rev | RDN | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $460M | 100.00% | $581M | 100.00% | RDN ×1.26 |
| Gross profit | $242M | 52.61% | $581M | 100.00% | RDN +47.4pp |
| Operating income | $84M | 18.37% | $179M | 30.79% | RDN +12.4pp |
| Pre-tax income | $94M | 20.48% | $151M | 25.95% | RDN +5.5pp |
| Net income | $77M | 16.72% | $116M | 19.96% | RDN +3.2pp |
| Stage | CRUS | RDN | Gap · A − B |
|---|---|---|---|
| Revenue | $460M100.00% | $581M100.00% | RDN ×1.26 |
| Gross profit | 52.61%$242M | 100.00%$581M | RDN +47.4pp |
| Operating income | 18.37%$84M | 30.79%$179M | RDN +12.4pp |
| Pre-tax income | 20.48%$94M | 25.95%$151M | RDN +5.5pp |
| Net income |
| 16.72%$77M |
| 19.96%$116M |
| RDN +3.2pp |
No shared counterparties.